Antibody-drug conjugate (ADC) technology back in cancer biotech spotlight

ADC trends, developments, and next hot targets: discover the upcoming ADC catalysts and public companies to benefit most in next 9 months

In mid-March 2023, Pfizer acquired Seagen ($SGEN) for $43B, making it the largest biopharma transaction in the last three years. Considered the leader in antibody-drug conjugate (ADC) technology, Seagen has 3 out of the 12 approved ADCs in the market. Pfizer forecasts the acquisition will bring in $10B in revenue by 2030. Following the deal, the ADC fie…